86 Morris Avenue
BUILDING FOR SUCCESS
Celgene Corporation is delivering the promise of science to patients and their families facing extraordinary challenges with cancer and inflammatory disease through innovative next generation therapies. Driving profitability are marketed products, which include THALOMID (thalidomide), ALKERAN (melphalan), Focalin™, cellular and tissue therapeutics, as well as the Ritalin family of drugs.
Celgene, as a leader in global biotechnology, has built a meaningfully integrated discovery, development and commercialization platform for drug and cell-based therapies that enables the company to continue to develop value within its therapeutic franchise areas of cancer and inflammatory diseases. This target-to-therapeutic platform integrates both small molecule and cell-based therapies and spans the critical functions required to generate a large and diverse pipeline of innovative next generation drugs and cell therapies that address the source of the disease and not just the symptoms.
RECENT PIPELINE HIGHLIGHTS
REVIMID: In February 2003 and April 2003, REVIMID received fast track designation from the FDA for the treatment of multiple myeloma and myelodysplastic syndromes, respectively. REVIMID is currently being tested in two pivotal Phase III FDA SPA trials for the treatment of multiple myeloma and metastatic melanoma. Furthermore, in May, at the International Myelodysplastic Syndromes meeting in Paris, France, REVIMID was the highlight of a study demonstrating medically meaningful erythroid and cytogenic response in MDS patients. That study, initiated by Dr. Alan List of the Moffitt Cancer Center, Tampa Florida, provided the foundation for Celgene to accelerate the potential approval of REVIMID by initiating four Phase II clinical trials; two multicenter Phase II studies in red blood cell transfusion dependent subjects with MDS with or without an associated 5Q minus cytogenetic abnormality and one phase II study in multiple myeloma.
THALOMID: Clinical investigators from leading cancer research centers around the world presented clinical data on THALOMID (thalidomide) in a broad range of hematological malignancies and solid tumor cancers at the Ninth Multiple Myeloma Workshop in Salamanca, Spain and at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, respectively. Several highlighted presentations provided new information on the potential of THALOMID across all stages of multiple myeloma as well as a wide range of solid tumor cancers, including renal cell carcinoma, prostate cancer and malignant melanoma.
ACTIMID™: Our next high-potential orally administered IMiD, is being evaluated in a Phase I/II clinical trial in refractory multiple myeloma and Phase II clinical trial in Prostate cancer. Interim data from an ongoing Phase I/II trial of ACTIMID in 18 relapsed and refractory multiple myeloma patients indicates that ACTIMID has anti-tumor activity in multiple myeloma and has an acceptable toxicity profile.
John W. Jackson - Executive Chairman
Sol J. Barer - Chief Executive Officer
Robert J. Hugin - President and Chief Operating Officer
816 articles with Celgene
Celgene Corporation Announces Additional $3 Billion Share Repurchase Authorization and Plans to Execute a $2 Billion Accelerated Share Repurchase Program
The planned ASR will utilize part of the existing Board authorized share repurchase program as well as part of the new authorization.
Most investors thought 2018 would be a big year for mergers and acquisitions in the biopharma industry because of changes to the tax law, and so far they’ve been right.
Celgene Corporation and Evotec AG announced they have inked a long-term strategic partnership to find and develop new cancer drugs.The partnership will lean on Evotec’s preclinical discovery and development platforms.
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that Evotec and Celgene Corporation ("Celgene") have entered into a long-term strategic drug discovery and development partnership to identify new therapeutics in oncology.
Celgne's head of business development, George Golumbeski, has also left the company.
5/18/2018In order to drive the manufacture of affordable generic drugs, the U.S. Food and Drug Administration is naming names of companies that have attempted to block competition.
5/15/2018Two years after entering into a licensing relationship Canada-based Zymeworks Inc. and Japanese pharma giant Daiichi Sankyo have entered into a second licensing agreement to expand immuno-oncology research with bispecific antibodies.
Jazz Sets Aside $57M to Settle Probe into Charitable Giving as DOJ Continues to Investigate Poten...
5/11/2018Jazz Pharmaceuticals set aside $57 million in the first quarter of 2018 to settle an investigation by the U.S. Attorney's Office for the District of Massachusetts regarding its support of 501(c)(3) organizations that provide financial assistance to Medicare patients.
The uses of viruses as therapeutics is growing, largely because new gene therapy treatments require viruses.
The stock market has been volatile so far this year, and biotech stocks are right there in the middle of things. Still, there are a few stocks that have taken a beating but will probably recover, and others that appear to be on their way up with every indication of continuing.
— Q1:18 total net product sales of $3,531 million, increased 20% Y/Y — Raising full-year 2018 revenue guidance to high end of previous range — Completion of Juno Therapeutics & Impact Biomedicines acquisitions will strengthen pipeline and capabilities — Submission of NDA and MAA for ozanimod in relapsing multiple sclerosis expected in Q1:19
Celgene is eying the first quarter of 2019 to submit a second New Drug Application (NDA) for multiple sclerosis treatment ozanimod.
To ask the question, “What are the top biotech stocks?” is to get trapped in a maze of definitions: small cap versus large cap, upcoming catalysts, trending, or a byzantine series of technical evaluations. Rather than to attempt an overall view, here are a variety of biotech stocks that are worth...
While the biopharma industry awaits news of an acquisition of Shire by Takeda Pharmaceuticals, it’s a good time to take a look back at the bigger deals so far this year.
Celgene Corporation Announces Appointment of Jennifer Dudinak to Senior Vice President of Global Regulatory Affairs
Jennifer will be responsible for regulatory strategy and execution across Celgene’s portfolio and will serve on the company's Executive Committee.
It may not seem like it, but biotech stocks are actually up over the past year. The iShares Nasdaq Biotechnology ETF (IBB) is up about 4%--nothing to write home about, but hardly a disastrous performance.
New Analyses from Pivotal Phase III Trials of Oral Ozanimod in Relapsing Multiple Sclerosis To Be Presented at the 2018 American Academy of Neurology Annual Meeting
Reductions in annualized relapse rates shown in pivotal trials with ozanimod were consistent in subgroups including baseline disability, gadolinium-enhanced lesion status and prior exposure to disease-modifying therapies versus interferon beta-1a
A nonprofit organization, Knowledge Ecology International (KEI), recently filed a lawsuit against the National Institutes of Health (NIH) over Gilead Sciences’ patents for a new chimeric antigen receptor T-cell (CAR-T) therapy.
Prothena Corporation announced it had shuttered its NEOD001 program for AL amyloidosis after the failure of its Phase IIb PRONTO study and Phase III VITAL study. Shares dropped 60 percent in premarket trading at the news.
Gilla Kaplan, Ph.D., retiring from Board of Directors after 20 years of service US health insurance expert Patricia Hemingway Hall elected to Board of Directors Juno Therapeutics co-founder and former CEO Hans Bishop elected to Board of Directors